Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

[Parent-child agreement in the health related quality of life (HRQOL) of children with attention-deficit/hyperactivity disorder (ADHD): a longitudinal study].

Rajmil L, Estrada MD, Herdman M, Serra-Sutton V, Tebé C, Izaguirre J, Alda JA, Alonso J, Riley AW, Forrest CB, Starfield B.

An Pediatr (Barc). 2009 Jun;70(6):553-61. doi: 10.1016/j.anpedi.2008.12.007. Epub 2009 May 7. Spanish.

2.

Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition.

Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G; ADORE Study Group.

Eur Child Adolesc Psychiatry. 2006 Dec;15 Suppl 1:I63-71. Erratum in: Eur Child Adolesc Psychiatry. 2009 Mar;18(3):194-6.

PMID:
17177018
3.

Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.

Matza LS, Secnik K, Mannix S, Sallee FR.

Pharmacoeconomics. 2005;23(8):777-90.

PMID:
16097840
4.

Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder.

Klassen AF, Miller A, Fine S.

Child Care Health Dev. 2006 Jul;32(4):397-406.

PMID:
16784495
5.

Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment.

Riley AW, Spiel G, Coghill D, Döpfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ; ADORE Study Group.

Eur Child Adolesc Psychiatry. 2006 Dec;15 Suppl 1:I38-45. Erratum in: Eur Child Adolesc Psychiatry. 2009 Mar;18(3):194-6.

PMID:
17177014
6.

Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.

Escobar R, Schacht A, Wehmeier PM, Wagner T.

J Clin Psychopharmacol. 2010 Apr;30(2):145-51. doi: 10.1097/JCP.0b013e3181d21763.

PMID:
20520287
7.

Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.

Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S.

Med Decis Making. 2005 Jan-Feb;25(1):56-70.

PMID:
15673582
8.

Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report.

Matza LS, Secnik K, Rentz AM, Mannix S, Sallee FR, Gilbert D, Revicki DA.

Qual Life Res. 2005 Apr;14(3):735-47.

PMID:
16022066
9.
10.
11.

Health-related quality of life of children with epilepsy in Hong Kong: how does it compare with that of youth with epilepsy in Canada?

Yam WK, Ronen GM, Cherk SW, Rosenbaum P, Chan KY, Streiner DL, Cheng SW, Fung CW, Ho JC, Kwong KL, Ma LC, Ma DK, Tsui KW, Wong V, Wong TY.

Epilepsy Behav. 2008 Apr;12(3):419-26. Epub 2007 Dec 26.

PMID:
18158271
12.

[Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children].

Escobar R, Hervas A, Soutullo C, Mardomingo MJ, Uruñuela A, Gilaberte I.

Actas Esp Psiquiatr. 2008 Sep-Oct;36(5):285-94. Spanish.

PMID:
18830848
13.

Agreement between children with cancer and their parents in reporting the child's health-related quality of life during a stay at the hospital and at home.

Speyer E, Herbinet A, Vuillemin A, Chastagner P, Briançon S.

Child Care Health Dev. 2009 Jul;35(4):489-95. doi: 10.1111/j.1365-2214.2009.00972.x.

PMID:
19638023
14.

Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD).

Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, Tan SS, Schulpen TW, Vlasveld L, Buitelaar JK.

Eur Child Adolesc Psychiatry. 2007 Aug;16(5):316-26. Epub 2007 May 4.

PMID:
17483870
15.

Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.

Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, Sumner CR, Kelsey DK.

Curr Med Res Opin. 2008 Feb;24(2):449-60. doi: 10.1185/030079908X253627 .

PMID:
18179733
16.

Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.

Flapper BC, Schoemaker MM.

Dev Med Child Neurol. 2008 Apr;50(4):294-9. doi: 10.1111/j.1469-8749.2008.02039.x.

17.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
18.

Quality of life of children with attention-deficit/hyper activity disorder.

Pongwilairat K, Louthrenoo O, Charnsil C, Witoonchart C.

J Med Assoc Thai. 2005 Aug;88(8):1062-6.

PMID:
16404833
19.

Impact of attention-deficit/hyperactivity disorder on health-related quality-of-l ife of specific learning disability children [corrected].

Karande S, Bhosrekar K.

Indian J Pediatr. 2009 Nov;76(11):1119-24. doi: 10.1007/s12098-009-0240-9. Erratum in: Indian J Pediatr. 2009 Dec;76(12):1246.

PMID:
20012790
20.

Quality of life in parents of children with attention-deficit-hyperactivity disorder in Hong Kong.

Xiang YT, Luk ES, Lai KY.

Aust N Z J Psychiatry. 2009 Aug;43(8):731-8. doi: 10.1080/00048670903001968.

PMID:
19629794
Items per page

Supplemental Content

Write to the Help Desk